HOME ABOUT US FIRST VISIT SURGERY EYE ISSUES CLINICAL TRIALS FAQS RESOURCES CONTACT US PAYMYBILL CLINICAL TRIALS Central Plains Eye (CPE) MDs was created in 2008 by Dr. C. Joseph Beck with one goal; to provide the best subspecialty eye care in a manner emphasizing the "Mom" model. In other words, if it's not what he would want to be applied in his own mother's care it won't be included at CPE. The doctor/patient relationship assumes compliance with recommended strategies against pathology. A subspecialty retina practice is not the environment to diagnose and then observe acute or progressive vision-threatening eye disease. Patients not wishing to partner with their physicians are strongly encouraged to seek attention elsewhere. It is hotly debated whether healthcare is a right. Regardless of one's opinion, the delivery of care requires credentialed personnel, equipped facilities, and approved supplies. These components are associated with significant costs, all of which increase predictably. Private practice physicians operate in the small business environment without government grants or "too big to fail" supports. One of the current burdens most threatening to doctors is physician-supplied drugs. This mandate alone can expose a single doctor practice to millions of dollars of risk annually. Accordingly, fees for services requested and rendered must be covered per an agreed-to fee schedule. Delays inherent to federally-administered systems (i.e. Medicare/Tricare) remain tolerable, but only barely. The forecast is stormy at best. For further information stop by our location in Wichita, Kansas. Or call us at (316) 712-4970 today. Participating in these Active Clinical Trials Participation in clinical trials is an indicator of best practice models. Entities funding these important studies do not award trial site status to just any practice. Coordinators for trials apply rigorous evaluation standards to potential investigating physicians and participating sites prior to considering inclusion. From the patient's perspective, clinical trials provide many benefits. Great attention is directed to those enrolled in a trial, and participation typically incorporates a significant safety net for rescue therapy should a protocol not prove effective clinically. The number of people that may benefit from information learned through clinical trials is untold. Medicine would be hopelessly behind were it not for these physician and patient supported studies. Retinal Vein Occlusion A Phase 3, Randomized, Masked, Controlled Trial to Study the Safety and Efficacy of Suprachoroidal CLS-TA in Combination with an Intravitreal anti-VEGF Agent in Subjects with Retinal Vein Occlusion. Sponsor: Clearside Biomedical, Inc. ClinicalTrials.gov Identifier: NCT03203447 Patient must be at least 18 years of age or older and diagnosed with retinal vein occlusion within 6 months of screening and be treatment naïve. Best corrected visual acuity in the study eye between 20/40 and 20/400 using a Snellen chart. Key Exclusion Criteria: Has in the study eye, used any topical ocular corticosteroid in the 10 days before treatment at Day 0; has at any time received any intraocular or periocular corticosteroid injection. Has a history of any vitreoretinal surgery ever in study eye or any ocular surgery within 3 months before randomization. Prior cataract extraction or YAG laser is allowed but must have been performed at least 3 months prior to baseline. Evidence of or history of any ophthalmic condition in the study eye that may have an associated neovascularization or edema component including, but not limited to, AMD, diabetic retinopathy, diabetic macular edema, retinal detachment, central serous chorioretinopathy, scleritis, optic neuropathy, retinitis pigmentosa, or glaucoma. Have active vitreous hemorrhage in the study eye within the last 90 days. History of MI or CVA within 90 days of treatment. Enrollment status: Currently Enrolling For more information on this trial Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium. Due to the lack of information generated in the pivotal phase III trials assessing potential effects of intravitreal injections of Macugen (pegaptanib sodium injection) on the corneal endothelium, the FDA requested clinical information from a 1-year (minimum) clinical study to support that there are no adverse effects on the corneal endothelium following intravitreal injections of Macugen. Sponsor: Valeant Pharmaceuticals International, Inc. ClinicalTrials.gov Identifier: NCT01573572 Patient must be 50 years of age or older and diagnosed with subfoveal neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, or Retinal Vein Occlusion. Best corrected visual acuity in the study eye between 20/20 and 20/400 using a Snellen chart. Key Exclusion Criteria: Unilateral ocular blunt trauma within one year of enrollment and no greater than 5% difference in central endothelial cell density between the 2 eyes, intraocular surgery (cataract surgery and surgery for glaucoma without tube shunt or mini-shunt) within one year of enrollment, anterior segment laser surgery (laser trabeculoplasty) performed within one year of enrollment, glaucoma tube-shunt surgery, previous history of corneal transplant in the study or non-study eye, presence of vitreous macular traction, previous therapeutic radiation in the region of the study eye, any treatment with an investigational agent in the past 30 days for any condition, severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation. Enrollment status: Currently Enrolling For more information on this trial Age-Related Macular Degeneration A Phase 3, Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1) Sponsor: Chengdu Kanghong Biotech Co.,Ltd. ClinicalTrials.gov Identifier: NCT03577899 Patient must be 50 years of age or older and diagnosed with subfoveal or juxtafoveal neovascular Age-Related Macular Degeneration with fluid affecting the fovea on OCT or fluorescein angiogram and have had NO prior ocular treatment or surgery for AMD. Best corrected visual acuity in the study eye between approx. 20/32 and 20/320 using a Snellen chart. Key Exclusion Criteria: Have a history of intraocular or periocular surgery within 3 months of baseline in the study eye, except in the case of lid surgery then within 1 month of baseline. Have prior pars plana vitrectomy, trabeculectomy or filtration surgery in the study eye. Have clinical evidence of significant diabetic retinopathy that could impact assessment of vision or affect central vision, diabetic macular edema or other vascular disease other than AMD. Have any use of long acting intraocular steroids, including implants, within 6 months prior. Have an allergy to povidone iodine or known serious allergy to the fluorescein sodium for injection in angiography. Enrollment status: Not Enrolling Yet For more information on this trial A Phase 3, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of RO6867461 in Patients with Diabetic Macular Edema (RHINE) Sponsor: Hoffmann-La Roche ClinicalTrials.gov Identifier: NCT03622593 Patient must be 18 years of age or older and diagnosed with diabetes mellitus (Type1 or Type 2), as defined by American Diabetes Association or per WHO criteria and current regular use of insulin or oral anti-hyperglycemic agents and HbA1c of < 10% within 2 months of study visit. Best corrected visual acuity in the study eye between approx. 20/40 and 20/320 using a Snellen chart. Must have evidence of diabetic macular edema involving the center of the fovea. Key Exclusion Criteria: Have active cancer within the past 12 months except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, and possible prostate cancer. Have renal failure requiring renal transplant, hemodialysis or peritoneal dialysis during the study. Have uncontrolled blood pressure. Have history of CVA or MI within 6 months prior to study start. Have uncontrolled glaucoma or high risk proliferative diabetic retinopathy, tractional retinal detachment, epiretinal membrane involving the fovea. Have had focal/grid laser, PRP, or intravitreal anti-VEGF within 3 months prior to study start. Had cataract surgery or YAG laser within 3 months of study start. Enrollment status: Not Enrolling Yet For more information on this trial For more information on any of our ongoing trials, contact Central Plains Eye MDs at (316) 712-4970 or click on the button to submit your questions. Closed / Completed Clinical Trial Clinical trials provide many benefits. Great attention is directed to those enrolled in a trial, and participation typically incorporates a significant safety net for rescue therapy should a protocol not prove effective clinically. The number of people that may benefit from information learned through clinical trials is untold. Medicine would be hopelessly behind were it not for these physician and patient supported studies. Thank you to those who participated in the following trials: Diabetic Retinopathy Sponsor: Aerpio Therapeutics ClinicalTrials.gov Identifier: NCT03197870 Age-Related Macular Degeneration Sponsor: Alcon Research ClinicalTrials.gov Identifier: NCT02307682 Diabetic Macular Edema Sponsor: Allegro Ophthalmic ClinicalTrials.gov Identifier: NCT01482871 Posterior Vitreous Detachment Sponsor: Allegro Ophthalmic ClinicalTrials.gov Identifier: NCT02435862 PRESERVE - Pegaptanib (Macugen) in diabetic macular edema (DME) Enrollment Status: CLOSED Contact Details Phone: (316) 712-4970 Email: info@cpemds.com Address: 7717 E 29th St N, Ste 100 Wichita, Kansas 67226-3444 Connect With Us Business Hours Mon - Thu 8:00 am - 5:00 pm Friday 8:00 am - 4:00 am Sat - Sun Closed RESET Content, including images, displayed on this website is protected by copyright laws. Downloading, republication, retransmission or reproduction of content on this website is strictly prohibited. Terms of Use | Privacy Policy Contact